CD274 and non-small cell lung carcinoma: Furthermore, ICIs such as programmed death protein-1/programmed cell death-1 ligand 1 (PD-1/PD-L1) monoclonal antibody had been approved for the treatment of stage IV NSCLC, based on the expression level of PD-L1 on tumor cells.